Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited. The use of neoadjuvant ...

Merck and Moderna show their cancer vaccine provides substantial benefit for melanoma patients for at least 3 years.